prikaz prve stranice dokumenta The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus
  Download
PDF 1.53 MB
Scientific paper - Original scientific paper
The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus
Diabetology & Metabolic Syndrome, 9 (2017); 97. https://doi.org/10.1186/s13098-017-0295-0
Božek, Tomislav; Blažeković, Antonela; Nikolac Perković, Matea; Gotovac Jerčić, Kristina; Šustar, Aleksandra; Smirčić-Duvnjak, Lea; Outeiro, Tiago F.; Pivac, Nela; Borovečki, Fran

Cite this document

Božek, T., Blažeković, A., Nikolac Perković, M., Gotovac Jerčić, K., Šustar, A., Smirčić Duvnjak, L. ... Borovečki, F. (2017). The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome, 9., 97. doi: 10.1186/s13098-017-0295-0

Božek, Tomislav, et al. "The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus." Diabetology & Metabolic Syndrome, vol. 9, 2017, p. 97. https://doi.org/10.1186/s13098-017-0295-0

Božek, Tomislav, Antonela Blažeković, Matea Nikolac Perković, Kristina Gotovac Jerčić, Aleksandra Šustar, Lea Smirčić Duvnjak, Tiago F. Outeiro, Nela Pivac and Fran Borovečki. "The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus." Diabetology & Metabolic Syndrome 9 (2017): 97. https://doi.org/10.1186/s13098-017-0295-0

Božek, T., et al. (2017) 'The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus', Diabetology & Metabolic Syndrome, 9, p. 97. doi: 10.1186/s13098-017-0295-0

Božek T, Blažeković A, Nikolac Perković M, Gotovac Jerčić K, Šustar A, Smirčić Duvnjak L, and sur.. The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome [Internet]. 2017 December 04 [cited 2024 April 18];9:97. doi: 10.1186/s13098-017-0295-0

T. Božek, et al., "The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus", Diabetology & Metabolic Syndrome, vol. 9, p. 97, December 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:450360. [Accessed: 18 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus
AuthorTomislav Božek
AuthorAntonela Blažeković
AuthorMatea Nikolac Perković
AuthorKristina Gotovac Jerčić
AuthorAleksandra Šustar
AuthorLea Smirčić-Duvnjak
AuthorTiago F. Outeiro
AuthorNela Pivac
AuthorFran Borovečki
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Background: Type II diabetes is an important health problem with a complex connection to obesity, leading to a broad range of cardiovascular complications. Insulin therapy often results in weight gain and does not always ensure adequate glycemic control. However, previous studies reported that insulin detemir is an efficient long-acting insulin with a weight sparing effect. The aim of this study was to determine the association of catechol O-methyltransferase (COMT) Val108/158Met and dopamine-beta-hydroxylase (DBH) 1021C/T polymorphisms with the effectiveness of insulin detemir in achieving glucose control and body weight control. Participants and methods: This 52-week observational study included 185 patients with inadequate glycemic control treated with premix insulin analogues, which were replaced with insulin aspart and insulin detemir, and 156 healthy controls. After DNA isolation from blood samples, genotyping of DBH-1021C/T polymorphism (rs1611115) and COMT Val108/158Met polymorphism (rs4680) was performed. ----- Results: Our results confirmed that insulin detemir did not lead to weight gain. The most significant finding was that A carriers (the combined AG and AA genotype) of the COMT Val108/158Met achieved significantly better hemoglobin A1c (HbA1c) values compared to patients carrying GG genotype. No association between DBH-1021C/T genotypes and weight and/or glucose control was detected in diabetes patients or in healthy control subjects. ----- Conclusions: This study showed that the presence of one or two A allele of the COMT Val108/158Met was associated with improved glycemic response, and with a better response to insulin detemir therapy in patients with type II diabetes, separating them as best candidates for detemir therapy.
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleDiabetology & Metabolic Syndrome
Numberingvol. 9, p. 97
p-ISSN1758-5996
DOIhttps://doi.org/10.1186/s13098-017-0295-0
URN:NBNurn:nbn:hr:105:450360
Publication2017-12-04
Document URLhttps://doi.org/10.1186/s13098-017-0295-0
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 09:04:43